Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma
Immunotherapy Advances · 30.12.2024 · 5 (1)
DOI: 10.1093/immadv/ltaf012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 22.03.2025. Verfasst von Hongyu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation of China, China Postdoctoral Science Foundation, Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital Affiliated to Fudan University.
Abstract (Originalsprache)
Introduction
The application of neoadjuvant immunotherapy in oesophageal squamous cell carcinoma (ESCC) reactivates anti-tumour immune responses and prolong postoperative survival. However, due to the heterogeneity of tumour microenvironment, limited patients have achieved pathological regression after treatment. The dual roles of B cells were recently highlighted in ESCC. The study aimed to investigate the role of B cell subclusters and the upstream signalling of B cell differentiation in ESCC resistant to immunotherapy.
Methods
Single-cell RNA sequencing was employed for ESCC specimens with distinct responses to neoadjuvant immunotherapy to map the landscape of intra-tumoural B cells.
Results
A novel subset of neuropeptide receptor, receptor activity-modifying protein 1 (RAMP1) positive B cells was revealed to accumulate in ESCC that is resistant to neoadjuvant immunotherapy. Stimulated by nociceptor neurons secreting calcitonin gene-related peptide (CGRP), RAMP1(+) B cells exhibit an immunosuppressive phenotype. The elevated secretion of immune-regulating cytokines by RAMP1(+) B cells blunts the cytotoxicity of Cluster of Differentiation (CD)8(+) T cell and leads to tumour immune evasion. A combination of RAMP1 blocker and anti-Programmed cell death protein (PD)-1 therapies synergistically reinvigorated anti-tumour immunity, reducing tumour progression in vitro.
Conclusion
The study suggests that RAMP1(+) B cells play a critical role in mediating resistance to neoadjuvant immunotherapy in ESCC. Targeting the CGRP-RAMP axis remodels B cells and enhance the efficacy of current immunotherapies, providing new strategies for overcoming treatment resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Thoracic Surgery, Jingjiang People's Hospital Affiliated to Yangzhou University, Jingjiang, China.
Förderung
- National Science Foundation of China
- China Postdoctoral Science Foundation
- Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital Affiliated to Fudan University
Zitieren
APA
Zhang, H., Zhang, Y., Zhou, P., Guo, Y., Jiang, L., & Gu, J. (2024). Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. Immunotherapy Advances, 5(1). https://doi.org/10.1093/immadv/ltaf012
Vancouver
Zhang H, Zhang Y, Zhou P, Guo Y, Jiang L, Gu J. Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. Immunotherapy Advances. 2024;5(1). doi:10.1093/immadv/ltaf012
BibTeX
@article{Zhang2024,
author = {Zhang, Hongyu and Zhang, Yuchen and Zhou, Pingjing and Guo, Yifan and Jiang, Liqun and Gu, Jie},
title = {Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma},
journal = {Immunotherapy Advances},
year = {2024},
volume = {5},
number = {1},
doi = {10.1093/immadv/ltaf012}
}
EUVIMED